亚特拉提利诺利德I通过抑制TLR4/NF-kB/NLRP3信号传递来缓解小鼠的实验性过敏反应
相关实验视频
Updated: Sep 11, 2025

10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.6K
Weiran Cai1, Zhijun Zhang1, Chenyan Shi1
1Department of Otolaryngology, Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, 528 Zhang Heng Road, Shanghai, 201203, China.
Open life sciences
|August 18, 2025
概括
阿特拉提利诺化物I (ATL-I) 通过抑制TLR4/NF-κB/NLRP3通路,有效地减少小鼠过敏性鼻炎症状. 这种天然化合物为过敏性鼻炎治疗提供了一个有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 过敏性鼻炎 (AR) 是一种常见的呼吸道疾病,与高免疫球蛋白E (IgE) 和鼻炎有关.
- 植物衍生化合物阿特拉提利诺化物I (ATL-I) 已被认为具有抗炎和抗氧化特性.
研究的目的:
- 在小鼠模型中研究ATL-I对过敏性鼻炎 (AR) 的保护作用.
- 阐明ATL-I在AR中的作用的潜在分子机制.
主要方法:
- 通过卵蛋白敏感化和挑战建立了一个AR小鼠模型.
- 通过监测过敏症状,血清细胞因子水平 (Th1/Th2) 和组胺/IgE度来评估ATL-I的影响.
- 西方涂抹和免疫组织化学用于评估Toll样受体4/核因子kB (TLR4/NF-kB) 途径和NOD样受体3 (NLRP3) 炎症酶激活.
主要成果:
- 在AR小鼠中,ATL-I的使用显著降低了打喷,摩擦,血清组胺和IgE水平.
- 在AR小鼠中,ATL-I治疗改善了Th1/Th2细胞因子平衡,这种平衡在AR小鼠中被破坏.
- ATL-I抑制了TLR4/NF-κB通路的激活,导致NLRP3炎症酶活性的抑制,并减少了鼻膜炎症.
结论:
- 通过减轻过敏反应,ATL-I证明了过敏性鼻炎的显著治疗潜力.
- 该机制涉及TLR4/NF-κB/NLRP3信号通路的抑制.
- ATL-I代表了一种有前途的天然化合物,用于开发新的AR治疗方法.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
Allergic Drug Reactions
978
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
978
Allergic Reactions
28.6K
Overview
28.6K
Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
Antibody Structure
61.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
61.2K

